Sarm1 as a Therapeutic Target for Chronic White Matter Pathology Following Experimental Traumatic Brain Injury
Abstract
Traumatic brain injury (TBI) can have long term consequences that include neurodegeneration and persistent symptoms. White matter tracts, such as the corpus callosum (CC), are particularly vulnerable and are associated with functional outcomes and potential neurodegenerative processes. Treatments are needed to protect axons from early traumatic axonal injury (TAI) and mitigate secondary mechanisms that lead to latest age neurodegeneration and atrophy. The SARM1 (sterile alpha and Toll/interleukin-1receptor motif containing 1) gene has been identified as a master executioner of the axon degeneration pathway and has become a significant target of interest in the development of therapeutic strategies to prevent axonal degradation. Our previous work demonstrated that mice with genetic deletion of Sarm1 exhibit significantly less acute axon damage and demyelination following a model of concussive TBI. This project aimed to determine if the constitutive absence of Sarm1 attenuates chronic white matter pathology and behavioral deficits following experimental TBI.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 19, 2021
- Accession Number
- AD1182968
Entities
People
- Donald V Jr Bradshaw
Organizations
- Uniformed Services University of the Health Sciences